WALTHAM, Mass.--(BUSINESS WIRE)--Sobi, a leading integrated global biopharmaceutical company dedicated to
rare and difficult-to-treat diseases, announced today that Trista
Morrison, an experienced corporate communications leader and former
journalist, has joined the company as vice president of communications
for North America.
“Sobi is a pioneer in rare and difficult-to-treat diseases, striving to
create a world where patients with these conditions are diagnosed at
birth and receive the care they need throughout their lives”
Morrison will support Sobi’s growth in the region by building the
communications function in North America and strengthening Sobi’s
connection with patients, caregivers, healthcare professionals,
advocacy groups and potential partners. She will also collaborate
closely with the Sobi global communications team on integrated,
worldwide communications initiatives.
Morrison’s more than 15 years in biopharmaceutical communications span
corporate, reporter and agency roles. Most recently, Morrison served as
director of corporate communications for Ironwood Pharmaceuticals, where
she led internal, external and brand communications as the company
transitioned from a research and development organization to a fully
integrated commercial biotechnology company. Prior to her role at
Ironwood, Morrison served as an editor and staff writer at BioWorld
Today, covering breaking news and trends in the biopharmaceutical
industry. Previously she served in various positions with
biopharmaceutical-focused public relations agency Porter Novelli Life
Sciences (formerly Atkins + Associates). Morrison was honored as one of
PR News’ Top
Women in PR in 2017, which recognizes communicators who have made
bold advances in the profession.
“Sobi is a pioneer in rare and difficult-to-treat diseases, striving to
create a world where patients with these conditions are diagnosed at
birth and receive the care they need throughout their lives,” said Rami
Levin, president of Sobi in North America. “This is an ambitious goal
that requires communication and partnership between multiple
stakeholders, and we look forward to working with Trista to advance this
important work in North America.”
“The Sobi team is incredibly passionate about the work we do and
dedicated to the patients and communities we serve. I am proud to be a
part of this team and look forward to increasing our communication with
key stakeholders as our business continues to grow,” said Morrison.
About Sobi™
Sobi is an international specialty healthcare company dedicated to rare
diseases. Sobi’s mission is to develop and deliver innovative therapies
and services to improve the lives of patients. The product portfolio is
primarily focused on Haemophilia, Inflammation and Genetic diseases.
Sobi also markets a portfolio of specialty and rare disease products
across Europe, the Middle East, North Africa and Russia for partner
companies. Sobi is a pioneer in biotechnology with world-class
capabilities in protein biochemistry and biologics manufacturing. In
2016, Sobi had total revenues of SEK 5.2 billion (USD 608 M) and about
760 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More
information is available at www.sobi.com.
